Indian pharma gets US FDA booster dose
Home › Indian pharma gets US FDA booster dose
 
With Cadila Healthcare, Glenmark Pharmaceuticals and Unichem Laboratories getting the US drug regulator’s nod this week to launch one generic drug each, the tally of abbreviated new drug application (ANDA) approvals for Indian firms went up to 129 this year - a 45% jump from 89 in the January-July period of last year.

“While on the one hand the US FDA is putting pressure on companies to upgrade their facilities to its standard, on the other hand it has now become more efficient by providing faster approvals to new drugs,” said Jagdish Dore, Managing Director at Sidvim Lifesciences, a firm specializing in preparing Indian companies for FDA inspections. (Business Standard: July 28, 2017)